

For Immediate Release

MedX Health Announces Patent Allowance for Use of Laser and Light Probe for Bone Healing

Notice of Allowance Covers Laser and Light Therapy Apparatus and Method for Bone Healing, Bone Growth Stimulation and Bone Cartilage Regeneration

Mississauga, ON – February 23, 2009 – MedX Health Corp., (TSXV.MDX) a global leader in developing drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced that the company has received a Notice of Allowance by the United States Patent & Trademark Office for its MedX Laser and Light Probe use and method for bone healing, bone growth stimulation and bone cartilage regeneration. The allowed claims cover the use of MedX's laser and light unit and the use of light therapy in various bone and cartilage healing situations such as carpal tunnel syndrome, tendonitis, bone growth and regeneration following a break, rheumatoid arthritis and wound healing.

“This notice of allowance from the U.S. Patent & Trademark Office broadens our device portfolio,” states Steve Guillen, president and CEO of MedX Health. “It is another important step toward our entry into the wound healing market, which we expect will take place this year,” adds Guillen.

The use of low level lasers and light therapy has been documented to be effective in promoting healing of bone, muscle, cartilage, tendon and ligaments. The newly allowed claims will cover The MedX Laser and Light Probe and its use in the treatment of damaged bone and cartilage. Specifically, the probe emits light, which triggers biological changes within the body, stimulating and accelerating cellular metabolic processes. The process of utilizing the MedX Laser and Light Probe increases the circulation by formulating new capillaries, and also stimulates collagen protein production, thus accelerating the healing process by helping damaged bone cells and tissue replace themselves more rapidly.

About MedX

MedX Health is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technology for use in numerous medical settings that provide patients with non-invasive, drug-free solutions for improving clinical outcomes. MedX's innovative Laser/Light Therapy devices enhance the rehabilitation process and are effective in pain relief, the rapid healing of tissue and bone damage, , and may help patients overcome their addiction to drugs, alcohol or tobacco.

MedX is expanding its distribution network and marketing program globally through strategic partnerships, while continuing to develop and acquire new dental, rehabilitation and wound care products. In particular, MedX plans to accelerate the development of a new product aimed at the

rapidly-growing wound care market. The newest patent allowance for bone growth joins several key existing patents, including “Photobandage” a new technology that allows a wound to be bathed in light and is designed to enhance the healing process. The Company intends to license their wound care technologies to one or more major wound care companies for further development, marketing and commercialization.

Contacts:Investors:

Steve Guillen
President and Chief Executive Officer
MedX Health Corp.
Phone: (905)826-0766
info@medxhealth.com

Media:

Terri Clevenger
Continuum Health Communications
Phone (203) 227-0209
Email: tclevenger@continuumhealthcom.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.